As tests of various vaccine manufacturers are underway, American company Moderna, Inc. decided to shape the test group from teenagers aged from 12 to 18 years old. Reuters wrote that on Thursday, December 10.
According to the news agency, the company "had dosed the first participants in a mid-to-late stage study testing its COVID-19 vaccine candidate in adolescents aged 12 to less than 18, and aims for data ahead of the 2021 school year".
The test group will comprise of 3,000 healthy people across the U.S.; they will get two doses of the company’s vaccine candidate, mRNA-1273. The second dose will be given 28 days after the first one.
"Moderna has submitted applications seeking emergency use authorization (EUA) in the United States and EU after full results from a late-stage study showed the vaccine was 94.1% effective in adults with no serious safety concerns. Rival Pfizer/BioNTech have also sought EUA after their coronavirus vaccine’s two-dose regimen proved 95% effective against COVID-19 and had no major safety issues", reads the story.